170 results
Page 7 of 9
6-K
EX-1.1
lsptsxc
26 Feb 20
Enlivex Therapeutics Closes $8.0 Million Registered Direct Offering
4:15pm
6-K
EX-99.1
tg0csen9f pr
26 Feb 20
Enlivex Therapeutics Closes $8.0 Million Registered Direct Offering
4:15pm
424B5
tm1jfkyrznb
26 Feb 20
Prospectus supplement for primary offering
8:23am
6-K
EX-99.1
08q9r3g7jc
24 Feb 20
Report of Foreign Private Issuer
6:30am
20-F/A
8bdbo4 6yr4k
23 Jan 20
Annual report (foreign) (amended)
4:31pm
424B5
f71 dbp62q
20 Nov 19
Prospectus supplement for primary offering
4:46pm
6-K
EX-99.2
1dtyqjz
14 Nov 19
Condensed Consolidated Financial Statements
7:30am
6-K
EX-99.1
8iz86zw6
4 Nov 19
Enlivex Therapeutics Announces Positive Interim Safety and Efficacy Data From Ongoing Trial of Off-The-Shelf Allocetra in Patients with Severe Sepsis
7:30am
6-K
EX-99.1
aq2ij 0kmm36aga
19 Aug 19
Report of Foreign Private Issuer
7:31am
6-K
EX-99.2
z9q9yyt c7
26 Jul 19
Condensed Consolidated Financial Statements
4:32pm
6-K
EX-99.1
brxr1d46p0n9q3a
16 Jul 19
Immunotherapy Company Enlivex Announces Dual Listing on the Tel-Aviv Stock Exchange
7:32am
424B3
gafr3
10 Jul 19
Prospectus supplement
8:18am
F-3
87a809babbcr3c6e41b
28 Jun 19
Shelf registration (foreign)
9:48am
F-3
5wvr9vhs
7 Jun 19
Shelf registration (foreign)
3:31pm
6-K
EX-99.2
7e8bxjlwrhxa50kqt
20 May 19
Condensed Consolidated Financial Statements
4:15pm
6-K
EX-99.4
dow2 0wauob
27 Mar 19
Securities Purchase Agreement
8:32am
6-K
EX-99.2
mpk7208g
27 Mar 19
Securities Purchase Agreement
8:32am
6-K
EX-99.6
ikiq5
27 Mar 19
Securities Purchase Agreement
8:32am